Brief: Portage Biotech Acquires Outstanding Minority Interest Of Invariant Natural Killer T Cell (Inkt) Agonist Platform
20/07/2022 14:33
July 20 (Reuters) - Portage Biotech Inc PRTG.O :
* PORTAGE BIOTECH ACQUIRES OUTSTANDING MINORITY INTEREST OF
INVARIANT NATURAL KILLER T CELL (INKT) AGONIST PLATFORM
Source text for Eikon: ID:nGNXbSrkzn
Further company coverage: PRTG.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsAlpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview
NASDAQ RESUMED AT 10:18 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:13 AM
Brief: Alpha Compute Signs Binding Gpu Contract, Leasing ALPHA-03 Cluster Under Four-Year, $81.7 Million Agreement In Its Missouri Superintelligence Factory
Alpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview